[{"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-001", "question": "A 5-month-old infant presents with exaggerated startle response to noise, progressive motor regression, and bilateral macular cherry-red spots. Serum hexosaminidase A and B levels are within normal limits. Genetic sequencing reveals a mutation in the GM2A gene. Which of the following is the correct diagnosis?", "options": ["Tay-Sachs disease", "Sandhoff disease", "GM2 activator deficiency", "Sialidosis type I", "Niemann-Pick disease type A"], "answer": "C", "answer_index": 2, "explanation": "The clinical phenotype mimics Tay-Sachs (Hex A deficiency) and Sandhoff (Hex A and B deficiency) diseases, including the cherry-red spot and startle response. However, normal enzyme levels with a mutation in GM2A indicate the AB variant of GM2 gangliosidosis, caused by a deficiency in the GM2 activator protein required for the interaction between the lipid substrate and the enzyme.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 5‑month-old infant; exaggerated startle response; progressive motor regression; bilateral macular cherry-red spots; normal serum hexosaminidase A and B; mutation in GM2A gene. This clinical picture is of a GM2 gangliosidosis (Tay‑Sachs/Sandhoff–like) but with normal Hex A/B levels, strongly indicating the AB variant due to GM2 activator deficiency, encoded by GM2A.\\nOption C explicitly names GM2 activator deficiency and correctly corresponds to GM2A mutation with a Tay‑Sachs–like phenotype. Options A (Tay‑Sachs) and B (Sandhoff) are excluded by the normal enzyme levels. Sialidosis type I (D) involves neuraminidase deficiency and typically presents later with myoclonus and other systemic features, not explained by GM2A mutation. Niemann‑Pick type A (E) features sphingomyelinase deficiency, hepatosplenomegaly, and cherry-red spots but not GM2A mutation or normal Hex with GM2 accumulation.\\nNo internal contradictions or underspecification are present; there is a single, clear best answer consistent with current biochemical genetics knowledge.\\nMinimal fix: Add the term “AB variant of GM2 gangliosidosis” in either the stem or explanation to explicitly link the clinical description to the named biochemical subtype for educational clarity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 5‑month-old infant; exaggerated startle response; progressive motor regression; bilateral macular cherry-red spots; normal serum hexosaminidase A and B; mutation in GM2A gene. This clinical picture is of a GM2 gangliosidosis (Tay‑Sachs/Sandhoff–like) but with normal Hex A/B levels, strongly indicating the AB variant due to GM2 activator deficiency, encoded by GM2A.\nOption C explicitly names GM2 activator deficiency and correctly corresponds to GM2A mutation with a Tay‑Sachs–like phenotype. Options A (Tay‑Sachs) and B (Sandhoff) are excluded by the normal enzyme levels. Sialidosis type I (D) involves neuraminidase deficiency and typically presents later with myoclonus and other systemic features, not explained by GM2A mutation. Niemann‑Pick type A (E) features sphingomyelinase deficiency, hepatosplenomegaly, and cherry-red spots but not GM2A mutation or normal Hex with GM2 accumulation.\nNo internal contradictions or underspecification are present; there is a single, clear best answer consistent with current biochemical genetics knowledge.\nMinimal fix: Add the term “AB variant of GM2 gangliosidosis” in either the stem or explanation to explicitly link the clinical description to the named biochemical subtype for educational clarity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-002", "question": "A 3-day-old neonate presents with intractable seizures refractory to phenobarbital, phenytoin, and levetiracetam. The EEG shows a burst-suppression pattern. Administration of intravenous pyridoxine yields no improvement. Subsequent administration of pyridoxal-5'-phosphate results in immediate cessation of clinical and electrographic seizure activity. Which enzyme is deficient?", "options": ["Antiquitin (ALDH7A1)", "Pyridox(am)ine 5'-phosphate oxidase (PNPO)", "Glutamic acid decarboxylase (GAD)", "GABA transaminase", "Succinic semialdehyde dehydrogenase"], "answer": "B", "answer_index": 1, "explanation": "Pyridoxine-dependent epilepsy (ALDH7A1 deficiency) responds to pyridoxine. However, patients with PNPO deficiency cannot convert pyridoxine to the active form, pyridoxal-5'-phosphate (PLP). They present with similar intractable seizures but require PLP specifically for treatment.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 3-day-old neonate with intractable seizures refractory to standard antiseizure meds; EEG burst–suppression pattern; lack of response to IV pyridoxine; immediate cessation of clinical and electrographic seizures after pyridoxal-5'-phosphate (PLP). This precisely matches pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency, in which pyridoxine cannot be converted to PLP, but exogenous PLP is effective.\\nAlternative choices: Antiquitin (ALDH7A1) deficiency (pyridoxine-dependent epilepsy) should respond to pyridoxine, so A is contradicted by the nonresponse. GAD, GABA transaminase, and succinic semialdehyde dehydrogenase deficiencies do not show specific rescue by PLP after pyridoxine failure in standard teaching and typically have different diagnostic/therapeutic patterns; none fits the very specific pyridoxine-nonresponsive but PLP-responsive phenotype as well as PNPO deficiency.\\nMain logical issues: None; the clinical response pattern and the explanation tightly support a single best answer.\\nMain medical accuracy issues: None significant; description of PNPO vs ALDH7A1-related epilepsy is accurate and current.\\nMinimal fix: Optionally add the word “selective” before “response to pyridoxal-5'-phosphate” in the stem to highlight the diagnostic specificity, but the item is already clear and valid.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 3-day-old neonate with intractable seizures refractory to standard antiseizure meds; EEG burst–suppression pattern; lack of response to IV pyridoxine; immediate cessation of clinical and electrographic seizures after pyridoxal-5'-phosphate (PLP). This precisely matches pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency, in which pyridoxine cannot be converted to PLP, but exogenous PLP is effective.\nAlternative choices: Antiquitin (ALDH7A1) deficiency (pyridoxine-dependent epilepsy) should respond to pyridoxine, so A is contradicted by the nonresponse. GAD, GABA transaminase, and succinic semialdehyde dehydrogenase deficiencies do not show specific rescue by PLP after pyridoxine failure in standard teaching and typically have different diagnostic/therapeutic patterns; none fits the very specific pyridoxine-nonresponsive but PLP-responsive phenotype as well as PNPO deficiency.\nMain logical issues: None; the clinical response pattern and the explanation tightly support a single best answer.\nMain medical accuracy issues: None significant; description of PNPO vs ALDH7A1-related epilepsy is accurate and current.\nMinimal fix: Optionally add the word “selective” before “response to pyridoxal-5'-phosphate” in the stem to highlight the diagnostic specificity, but the item is already clear and valid.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-003", "question": "A 35-year-old male with Myotonic Dystrophy Type 1 presents for emergency appendectomy. Following induction with propofol and succinylcholine, the patient develops generalized muscle rigidity, making ventilation impossible. The heart rate is 110 bpm and temperature is 37.2°C. Which of the following best explains the pathophysiology of this reaction?", "options": ["Uncontrolled calcium release from the sarcoplasmic reticulum via the ryanodine receptor", "Prolonged depolarization of the motor endplate causing sodium channel inactivation failure", "Exaggerated contracture due to sodium channel hyperexcitability distal to the neuromuscular junction", "Denervation hypersensitivity leading to massive potassium efflux", "Deficiency of pseudocholinesterase leading to prolonged blockade"], "answer": "C", "answer_index": 2, "explanation": "This is a succinylcholine-induced myotonic contracture, not Malignant Hyperthermia (MH). In myotonic dystrophy, the muscle membrane is hyperexcitable. Succinylcholine causes a sustained, generalized contracture that acts as a 'chemical splint,' preventing ventilation. Unlike MH, it is not mediated by the RYR1 receptor and does not respond to dantrolene.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Known myotonic dystrophy type 1, exposure to succinylcholine, immediate generalized muscle rigidity making ventilation impossible, but normal body temperature and only mild tachycardia. The vignette explicitly contrasts with malignant hyperthermia (no hyperthermia, no escalating vitals) and focuses on succinylcholine-triggered contracture in a myotonic patient.\\nPathophysiologically, myotonic dystrophy involves membrane hyperexcitability/myotonia due to ion channel dysfunction distal to the neuromuscular junction. Succinylcholine depolarizes the endplate and, in these patients, triggers sustained myotonic contracture (“chemical splint”), best captured by option C.\\nOption A describes malignant hyperthermia via RYR1-mediated Ca²⁺ release, which is inconsistent with normal temperature and the explanation. B incorrectly attributes the problem to endplate depolarization/sodium channel inactivation failure; E concerns prolonged paralysis, not forceful contracture; D fits denervation states (burns, UMN lesions) and hyperkalemia, not primary myotonia.\\nNo internal contradictions or need for extra assumptions are present; one best answer exists and matches the key.\\nMain medical accuracy issues: none significant; the teaching point is contemporary and correct.\\nMinimal fix: Add explicit statement that labs/equipment for MH are normal/unchanged to further distinguish from malignant hyperthermia, though not strictly necessary.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Known myotonic dystrophy type 1, exposure to succinylcholine, immediate generalized muscle rigidity making ventilation impossible, but normal body temperature and only mild tachycardia. The vignette explicitly contrasts with malignant hyperthermia (no hyperthermia, no escalating vitals) and focuses on succinylcholine-triggered contracture in a myotonic patient.\nPathophysiologically, myotonic dystrophy involves membrane hyperexcitability/myotonia due to ion channel dysfunction distal to the neuromuscular junction. Succinylcholine depolarizes the endplate and, in these patients, triggers sustained myotonic contracture (“chemical splint”), best captured by option C.\nOption A describes malignant hyperthermia via RYR1-mediated Ca²⁺ release, which is inconsistent with normal temperature and the explanation. B incorrectly attributes the problem to endplate depolarization/sodium channel inactivation failure; E concerns prolonged paralysis, not forceful contracture; D fits denervation states (burns, UMN lesions) and hyperkalemia, not primary myotonia.\nNo internal contradictions or need for extra assumptions are present; one best answer exists and matches the key.\nMain medical accuracy issues: none significant; the teaching point is contemporary and correct.\nMinimal fix: Add explicit statement that labs/equipment for MH are normal/unchanged to further distinguish from malignant hyperthermia, though not strictly necessary.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-004", "question": "A patient with a known diagnosis of Erythropoietic Protoporphyria (EPP) is undergoing a prolonged laparotomy. Which of the following intraoperative interventions is most critical to prevent cutaneous injury in this specific patient?", "options": ["Avoidance of nitrous oxide", "Placement of yellow filters over the operating lights", "Strict avoidance of volatile anesthetics", "Administration of high-dose corticosteroids", "Maintenance of normothermia to prevent precipitation"], "answer": "B", "answer_index": 1, "explanation": "Patients with EPP accumulate protoporphyrin IX, which is phototoxic upon exposure to light in the violet/blue spectrum (Soret band, ~400-410 nm). Standard operating lights emit significant energy in this range, causing severe phototoxic skin burns and potential intestinal injury during laparotomy. Yellow filters block this specific wavelength.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Known diagnosis of erythropoietic protoporphyria (EPP); prolonged laparotomy; question asks for the intraoperative intervention most critical to prevent cutaneous injury in this specific disorder. EPP involves accumulation of protoporphyrin IX, which is strongly activated by blue–violet light around 400 nm (Soret band). Operating room lights emit in this range, causing severe photosensitivity reactions and burns, especially with prolonged exposure of skin and viscera during laparotomy. The standard preventive measure is optical filtering of OR lights, typically using yellow filters, to attenuate the hazardous wavelengths. Thus option B directly addresses the pathophysiology and risk. Other options (avoidance of nitrous oxide, volatile agents, corticosteroids, or specific temperature management) are not specific or critical to preventing cutaneous phototoxic injury in EPP and lack an evidence-based connection to the described risk. No internal contradictions, underspecification, or multiple defensible answers are present. Minimal fix: Add a brief phrase in the stem specifying concern about “light-induced skin/visceral burns” to more explicitly cue the phototoxic mechanism, though the current stem is already sufficient.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Known diagnosis of erythropoietic protoporphyria (EPP); prolonged laparotomy; question asks for the intraoperative intervention most critical to prevent cutaneous injury in this specific disorder. EPP involves accumulation of protoporphyrin IX, which is strongly activated by blue–violet light around 400 nm (Soret band). Operating room lights emit in this range, causing severe photosensitivity reactions and burns, especially with prolonged exposure of skin and viscera during laparotomy. The standard preventive measure is optical filtering of OR lights, typically using yellow filters, to attenuate the hazardous wavelengths. Thus option B directly addresses the pathophysiology and risk. Other options (avoidance of nitrous oxide, volatile agents, corticosteroids, or specific temperature management) are not specific or critical to preventing cutaneous phototoxic injury in EPP and lack an evidence-based connection to the described risk. No internal contradictions, underspecification, or multiple defensible answers are present. Minimal fix: Add a brief phrase in the stem specifying concern about “light-induced skin/visceral burns” to more explicitly cue the phototoxic mechanism, though the current stem is already sufficient.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-005", "question": "A 45-year-old female with breast cancer is being treated with tamoxifen. She develops major depressive disorder. Which of the following antidepressants is contraindicated due to a pharmacokinetic interaction that would reduce the oncologic efficacy of her breast cancer treatment?", "options": ["Venlafaxine", "Escitalopram", "Paroxetine", "Desvenlafaxine", "Mirtazapine"], "answer": "C", "answer_index": 2, "explanation": "Tamoxifen is a prodrug that requires conversion to its active metabolite, endoxifen, primarily via the CYP2D6 enzyme. Paroxetine (and fluoxetine) is a potent CYP2D6 inhibitor, which can significantly lower endoxifen levels and potentially increase the risk of breast cancer recurrence. Venlafaxine and escitalopram have minimal effect on CYP2D6.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 45-year-old woman with breast cancer on tamoxifen; needs an antidepressant; question asks which option is contraindicated due to a pharmacokinetic interaction that would reduce tamoxifen’s oncologic efficacy. Tamoxifen is a prodrug activated mainly by CYP2D6 to endoxifen. Strong CYP2D6 inhibition would reduce active metabolite levels and efficacy.\\nParoxetine is a well-established strong CYP2D6 inhibitor and is specifically avoided with tamoxifen. Venlafaxine and desvenlafaxine have minimal CYP2D6 inhibition at therapeutic doses and are often recommended when treating hot flashes or depression in tamoxifen users. Escitalopram is a weak CYP2D6 inhibitor and generally acceptable. Mirtazapine has negligible CYP2D6 inhibition. Thus C is uniquely best.\\nNo major logical issues: the stem clearly asks for the one agent contraindicated because of a pharmacokinetic interaction compromising tamoxifen activation; only paroxetine fits this profile among the listed choices.\\nMedical accuracy issues: Explanation is aligned with current evidence and standard teaching; nuance about the strength of evidence linking CYP2D6 inhibition to recurrence risk could be added but is not necessary for exam level.\\nMinimal fix: None required; item is already unambiguous and accurate as written.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 45-year-old woman with breast cancer on tamoxifen; needs an antidepressant; question asks which option is contraindicated due to a pharmacokinetic interaction that would reduce tamoxifen’s oncologic efficacy. Tamoxifen is a prodrug activated mainly by CYP2D6 to endoxifen. Strong CYP2D6 inhibition would reduce active metabolite levels and efficacy.\nParoxetine is a well-established strong CYP2D6 inhibitor and is specifically avoided with tamoxifen. Venlafaxine and desvenlafaxine have minimal CYP2D6 inhibition at therapeutic doses and are often recommended when treating hot flashes or depression in tamoxifen users. Escitalopram is a weak CYP2D6 inhibitor and generally acceptable. Mirtazapine has negligible CYP2D6 inhibition. Thus C is uniquely best.\nNo major logical issues: the stem clearly asks for the one agent contraindicated because of a pharmacokinetic interaction compromising tamoxifen activation; only paroxetine fits this profile among the listed choices.\nMedical accuracy issues: Explanation is aligned with current evidence and standard teaching; nuance about the strength of evidence linking CYP2D6 inhibition to recurrence risk could be added but is not necessary for exam level.\nMinimal fix: None required; item is already unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-006", "question": "A patient with schizophrenia is started on clozapine. Three weeks later, he presents with fever, tachycardia, and eosinophilia. A diagnosis of clozapine-induced myocarditis is suspected and confirmed. After recovery, the psychiatric team considers a rechallenge due to treatment resistance. Under current expert consensus guidelines, which medication should be co-administered during the rechallenge to reduce the risk of recurrence?", "options": ["Lithium", "Propranolol", "Prednisone", "Lisinopril", "Metoprolol"], "answer": "D", "answer_index": 3, "explanation": "While clozapine rechallenge after myocarditis is high-risk and generally discouraged, when deemed necessary, protocols often utilize an ACE inhibitor (like lisinopril) or an ARB prophylactically. This is based on the hypothesis that the renin-angiotensin-aldosterone system plays a role in the inflammatory/fibrotic pathogenesis of the myocarditis.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N. Verdict on keyed answer: No defensible answer. The vignette: clozapine-induced myocarditis, later clozapine rechallenge, asks which medication should be co-administered to reduce recurrence risk “under current expert consensus guidelines.” The keyed answer (lisinopril) is justified in the explanation as based on a hypothesis about RAAS and myocarditis. However, there is no widely accepted expert-consensus or guideline-level recommendation that ACE inhibitors or ARBs be routinely co-administered specifically to prevent recurrence of clozapine-induced myocarditis during rechallenge. Published case reports/series mention intensive monitoring; some cardiology management of LV dysfunction may use ACEi, but that is treatment of HF, not proven prophylaxis for recurrence. None of the listed options (lithium, beta-blockers, prednisone, lisinopril, metoprolol) has established, guideline-supported evidence as prophylaxis for clozapine myocarditis, so no option is clearly “best” per the stem’s standard. Main medical issue: overstatement of “current expert consensus guidelines” and implying a standard of care that does not exist. Minimal fix: Reframe the question to ask about a hypothesized, experimental strategy reported in some protocols, or change the stem to remove “expert consensus guidelines” and present it explicitly as a proposed RAAS-modulating approach rather than standard care.\\n\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N. Verdict on keyed answer: No defensible answer. The vignette: clozapine-induced myocarditis, later clozapine rechallenge, asks which medication should be co-administered to reduce recurrence risk “under current expert consensus guidelines.” The keyed answer (lisinopril) is justified in the explanation as based on a hypothesis about RAAS and myocarditis. However, there is no widely accepted expert-consensus or guideline-level recommendation that ACE inhibitors or ARBs be routinely co-administered specifically to prevent recurrence of clozapine-induced myocarditis during rechallenge. Published case reports/series mention intensive monitoring; some cardiology management of LV dysfunction may use ACEi, but that is treatment of HF, not proven prophylaxis for recurrence. None of the listed options (lithium, beta-blockers, prednisone, lisinopril, metoprolol) has established, guideline-supported evidence as prophylaxis for clozapine myocarditis, so no option is clearly “best” per the stem’s standard. Main medical issue: overstatement of “current expert consensus guidelines” and implying a standard of care that does not exist. Minimal fix: Reframe the question to ask about a hypothesized, experimental strategy reported in some protocols, or change the stem to remove “expert consensus guidelines” and present it explicitly as a proposed RAAS-modulating approach rather than standard care.\n", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-007", "question": "A 22-year-old male presents with hypersomnia, hyperphagia, and hypersexuality occurring in distinct episodes lasting two weeks, separated by months of normal behavior. During episodes, he exhibits derealization. Which of the following pharmacologic agents has the strongest evidence for preventing future episodes of this syndrome?", "options": ["Modafinil", "Lithium", "Methylphenidate", "Fluoxetine", "Lorazepam"], "answer": "B", "answer_index": 1, "explanation": "The clinical presentation is classic for Kleine-Levin Syndrome (KLS). While symptomatic treatment involves stimulants, Lithium is the mood stabilizer with the most reported efficacy in reducing the frequency and intensity of the cycling episodes, although evidence is limited to case series and small studies.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: 22-year-old male; recurrent, distinct episodes lasting ~2 weeks with months of normal behavior between; triad of hypersomnia, hyperphagia, hypersexuality; associated derealization. This is classic for Kleine–Levin syndrome (KLS), a rare recurrent hypersomnia disorder. The question asks which pharmacologic agent has the strongest evidence for *preventing future episodes*.\\n\\nLithium has the best (though still limited) evidence from case series and small observational studies for reducing frequency/severity of KLS episodes. Stimulants such as modafinil or methylphenidate may help symptomatic wakefulness during episodes but have not been shown to prevent recurrences. Fluoxetine and lorazepam lack evidence as prophylaxis for KLS and are not standard of care for this indication.\\n\\nThere is a single best answer (lithium) that clearly aligns with the stated goal of prophylaxis rather than acute symptom management, so the item is logically coherent and keyed correctly.\\n\\nMinimal fix: Add a brief phrase such as “According to observational reports and case series…” to the stem or explanation to acknowledge the limited evidence base while preserving lithium as the best available choice.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: 22-year-old male; recurrent, distinct episodes lasting ~2 weeks with months of normal behavior between; triad of hypersomnia, hyperphagia, hypersexuality; associated derealization. This is classic for Kleine–Levin syndrome (KLS), a rare recurrent hypersomnia disorder. The question asks which pharmacologic agent has the strongest evidence for *preventing future episodes*.\n\nLithium has the best (though still limited) evidence from case series and small observational studies for reducing frequency/severity of KLS episodes. Stimulants such as modafinil or methylphenidate may help symptomatic wakefulness during episodes but have not been shown to prevent recurrences. Fluoxetine and lorazepam lack evidence as prophylaxis for KLS and are not standard of care for this indication.\n\nThere is a single best answer (lithium) that clearly aligns with the stated goal of prophylaxis rather than acute symptom management, so the item is logically coherent and keyed correctly.\n\nMinimal fix: Add a brief phrase such as “According to observational reports and case series…” to the stem or explanation to acknowledge the limited evidence base while preserving lithium as the best available choice.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-008", "question": "A 60-year-old female undergoes a laparoscopic cholecystectomy for symptomatic cholelithiasis. Final pathology reveals an incidental gallbladder adenocarcinoma invading the perimuscular connective tissue (T1b) without extension into the liver. The cystic duct margin is negative. What is the appropriate next step in management?", "options": ["Observation only", "Adjuvant chemotherapy with Gemcitabine/Cisplatin", "Radiation therapy to the gallbladder fossa", "Resection of liver segments IVb and V with portal lymphadenectomy", "Endoscopic Retrograde Cholangiopancreatography (ERCP) with stenting"], "answer": "D", "answer_index": 3, "explanation": "For T1a gallbladder cancer (invading lamina propria), simple cholecystectomy is curative. However, for T1b (invading muscle layer) and greater, there is a significant risk of lymph node metastasis and recurrence. The standard of care is radical cholecystectomy, which includes resection of the liver bed (segments IVb and V) and a portal lymphadenectomy.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 60-year-old with incidental gallbladder adenocarcinoma after laparoscopic cholecystectomy; pathologic stage T1b with invasion into perimuscular connective tissue, no liver extension, negative cystic duct margin. The question asks the next step in management. For T1a (lamina propria), simple cholecystectomy suffices; for T1b and higher, there is higher risk of nodal disease and local recurrence, and guidelines recommend radical re-resection.\\nChoice D (resection of liver segments IVb and V with portal lymphadenectomy) correctly describes radical cholecystectomy and matches contemporary surgical oncology standards for incidental T1b gallbladder cancer without distant disease.\\nOther options: A (observation) is insufficient for T1b, which warrants re-resection. B (adjuvant gemcitabine/cisplatin) is used in more advanced/unresectable or postoperative high-risk settings but not as sole next step when curative re-resection is indicated. C (radiation alone) is not standard primary therapy here. E (ERCP with stenting) is irrelevant as there is no biliary obstruction.\\nMain medical issue: minor wording inconsistency between explanation (“invading muscle layer”) and stem (“perimuscular connective tissue”), but both are within T1b definition.\\nMinimal fix: Clarify staging in stem and explanation to consistently describe T1b as invading muscle and/or perimuscular connective tissue per chosen staging system.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 60-year-old with incidental gallbladder adenocarcinoma after laparoscopic cholecystectomy; pathologic stage T1b with invasion into perimuscular connective tissue, no liver extension, negative cystic duct margin. The question asks the next step in management. For T1a (lamina propria), simple cholecystectomy suffices; for T1b and higher, there is higher risk of nodal disease and local recurrence, and guidelines recommend radical re-resection.\nChoice D (resection of liver segments IVb and V with portal lymphadenectomy) correctly describes radical cholecystectomy and matches contemporary surgical oncology standards for incidental T1b gallbladder cancer without distant disease.\nOther options: A (observation) is insufficient for T1b, which warrants re-resection. B (adjuvant gemcitabine/cisplatin) is used in more advanced/unresectable or postoperative high-risk settings but not as sole next step when curative re-resection is indicated. C (radiation alone) is not standard primary therapy here. E (ERCP with stenting) is irrelevant as there is no biliary obstruction.\nMain medical issue: minor wording inconsistency between explanation (“invading muscle layer”) and stem (“perimuscular connective tissue”), but both are within T1b definition.\nMinimal fix: Clarify staging in stem and explanation to consistently describe T1b as invading muscle and/or perimuscular connective tissue per chosen staging system.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-009", "question": "A trauma patient presents with a Zone I retroperitoneal hematoma following a high-speed motor vehicle collision. Hemodynamics are transiently stabilized with fluids. CT scan shows the hematoma is centered around the supramesocolic midline. Intraoperatively, what is the mandated management strategy?", "options": ["Observation if the hematoma is not expanding", "Immediate exploration of the hematoma", "Angiographic embolization", "Packing and temporary closure", "REBOA placement in Zone 1"], "answer": "B", "answer_index": 1, "explanation": "Zone I retroperitoneal hematomas (central, midline) in blunt trauma are presumed to involve the aorta, vena cava, or proximal branches (celiac/SMA). Unlike Zone II (flank/kidney) or Zone III (pelvic) hematomas which may be managed non-operatively or with angioembolization if stable, a Zone I hematoma mandates surgical exploration to rule out or repair catastrophic vascular injury.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: “Zone I retroperitoneal hematoma,” “high-speed motor vehicle collision” (blunt mechanism), “hemodynamics are transiently stabilized with fluids,” “CT scan shows the hematoma is centered around the supramesocolic midline,” and “Intraoperatively, what is the mandated management strategy?” These clearly indicate a central supramesocolic Zone I hematoma discovered at laparotomy in a trauma setting. Standard trauma surgery teaching is that central Zone I retroperitoneal hematomas in blunt trauma mandate exploration because of the high likelihood of major aortic or caval injury. Thus immediate exploration (B) is appropriate.\\nOther options: Observation (A) is contraindicated for central Zone I hematomas at laparotomy. Angiographic embolization (C) is not the mandated intraoperative strategy and is less appropriate once the abdomen is open. Packing and temporary closure (D) may be used adjunctively but does not replace mandated exploration of the hematoma. REBOA in Zone 1 (E) is a pre-/perioperative resuscitative adjunct, not the definitive intraoperative management of a seen Zone I hematoma.\\nMain medical/logical issues: None significant; the question is specific and aligned with ATLS/trauma surgery principles.\\nMinimal fix: Explicitly state “at laparotomy a large central supramesocolic Zone I hematoma is visualized” to reinforce the intraoperative context.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: “Zone I retroperitoneal hematoma,” “high-speed motor vehicle collision” (blunt mechanism), “hemodynamics are transiently stabilized with fluids,” “CT scan shows the hematoma is centered around the supramesocolic midline,” and “Intraoperatively, what is the mandated management strategy?” These clearly indicate a central supramesocolic Zone I hematoma discovered at laparotomy in a trauma setting. Standard trauma surgery teaching is that central Zone I retroperitoneal hematomas in blunt trauma mandate exploration because of the high likelihood of major aortic or caval injury. Thus immediate exploration (B) is appropriate.\nOther options: Observation (A) is contraindicated for central Zone I hematomas at laparotomy. Angiographic embolization (C) is not the mandated intraoperative strategy and is less appropriate once the abdomen is open. Packing and temporary closure (D) may be used adjunctively but does not replace mandated exploration of the hematoma. REBOA in Zone 1 (E) is a pre-/perioperative resuscitative adjunct, not the definitive intraoperative management of a seen Zone I hematoma.\nMain medical/logical issues: None significant; the question is specific and aligned with ATLS/trauma surgery principles.\nMinimal fix: Explicitly state “at laparotomy a large central supramesocolic Zone I hematoma is visualized” to reinforce the intraoperative context.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-010", "question": "A 32-year-old female presents with acute vision loss in the left eye and retrobulbar pain. Examination reveals a central scotoma and an afferent pupillary defect. MRI shows enhancement of the left optic nerve. She is diagnosed with optic neuritis. According to the Optic Neuritis Treatment Trial (ONTT), which treatment regimen is contraindicated because it increases the rate of recurrence?", "options": ["Intravenous methylprednisolone followed by oral prednisone", "Oral prednisone alone", "Intravenous immunoglobulin (IVIG)", "Plasma exchange", "Observation alone"], "answer": "B", "answer_index": 1, "explanation": "The ONTT demonstrated that treatment with oral prednisone alone (at standard doses) not only failed to improve visual outcome compared to placebo but actually significantly increased the rate of recurrent optic neuritis. The standard of care is IV methylprednisolone (often followed by an oral taper) or observation.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Ophthalmology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young woman with typical demyelinating optic neuritis; question explicitly references the Optic Neuritis Treatment Trial (ONTT) and asks which regimen is contraindicated because it increases recurrence. ONTT is well known to have shown that standard-dose oral prednisone alone increased recurrence rates versus placebo, whereas IV methylprednisolone (with or without oral taper) improved short‑term recovery and did not increase recurrence. Observation is acceptable and not associated with increased recurrence. IVIG and plasma exchange are not standard ONTT arms and have no evidence of increasing recurrence.\\nMain logical issue(s): None; the question is tightly focused, and only one option (oral prednisone alone) matches the specific ONTT finding of increased recurrence. Other choices are clearly distinguishable and not supported by ONTT as harmful in this way.\\nMain medical accuracy issue(s): None substantive; description of ONTT findings and standard of care is accurate and aligned with modern teaching.\\nMinimal fix: Optionally specify “standard-dose oral prednisone alone (1 mg/kg/day)” to mirror the original ONTT regimen more precisely, but this is not required for clarity or correctness.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young woman with typical demyelinating optic neuritis; question explicitly references the Optic Neuritis Treatment Trial (ONTT) and asks which regimen is contraindicated because it increases recurrence. ONTT is well known to have shown that standard-dose oral prednisone alone increased recurrence rates versus placebo, whereas IV methylprednisolone (with or without oral taper) improved short‑term recovery and did not increase recurrence. Observation is acceptable and not associated with increased recurrence. IVIG and plasma exchange are not standard ONTT arms and have no evidence of increasing recurrence.\nMain logical issue(s): None; the question is tightly focused, and only one option (oral prednisone alone) matches the specific ONTT finding of increased recurrence. Other choices are clearly distinguishable and not supported by ONTT as harmful in this way.\nMain medical accuracy issue(s): None substantive; description of ONTT findings and standard of care is accurate and aligned with modern teaching.\nMinimal fix: Optionally specify “standard-dose oral prednisone alone (1 mg/kg/day)” to mirror the original ONTT regimen more precisely, but this is not required for clarity or correctness.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-011", "question": "A neonate with Down syndrome presents with hepatosplenomegaly and a high white blood cell count consisting of blasts. A diagnosis of Transient Myeloproliferative Disorder (TMD) is made. Mutation analysis of the blasts would most likely reveal a mutation in which gene?", "options": ["JAK2", "GATA1", "RUNX1", "ETV6", "BCR-ABL"], "answer": "B", "answer_index": 1, "explanation": "TMD in Down syndrome is uniquely associated with somatic mutations in the GATA1 gene, which encodes a transcription factor required for erythroid and megakaryocytic differentiation. While TMD often resolves spontaneously, these patients are at increased risk for developing Acute Megakaryoblastic Leukemia (AMKL) later in childhood.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Neonate, Down syndrome, hepatosplenomegaly, leukocytosis with blasts, specifically diagnosed as Transient Myeloproliferative Disorder (TMD). TMD in infants with trisomy 21 is classically and specifically associated with acquired (somatic) mutations in the GATA1 gene in megakaryoblasts. This makes GATA1 the single best answer.\\nOption appraisal: \\n- B (GATA1) fits the well-established association between Down syndrome–related TMD/acute megakaryoblastic leukemia and GATA1 truncating mutations.\\n- A (JAK2) is seen in myeloproliferative neoplasms (e.g., polycythemia vera, essential thrombocythemia), not specifically in neonatal TMD of Down syndrome.\\n- C (RUNX1) and D (ETV6) are leukemia-related transcription factor genes but do not define TMD in Down syndrome.\\n- E (BCR-ABL) is characteristic of CML and some ALL, not TMD.\\nMain logical issues: None; the stem name-checks TMD, which directly cues the unique gene association.\\nMain medical accuracy issues: None; pathophysiologic association and clinical context are up to date and standard.\\nMinimal fix: No essential change needed; optionally add that the mutation is somatic in megakaryoblasts to increase precision.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Neonate, Down syndrome, hepatosplenomegaly, leukocytosis with blasts, specifically diagnosed as Transient Myeloproliferative Disorder (TMD). TMD in infants with trisomy 21 is classically and specifically associated with acquired (somatic) mutations in the GATA1 gene in megakaryoblasts. This makes GATA1 the single best answer.\nOption appraisal: \n- B (GATA1) fits the well-established association between Down syndrome–related TMD/acute megakaryoblastic leukemia and GATA1 truncating mutations.\n- A (JAK2) is seen in myeloproliferative neoplasms (e.g., polycythemia vera, essential thrombocythemia), not specifically in neonatal TMD of Down syndrome.\n- C (RUNX1) and D (ETV6) are leukemia-related transcription factor genes but do not define TMD in Down syndrome.\n- E (BCR-ABL) is characteristic of CML and some ALL, not TMD.\nMain logical issues: None; the stem name-checks TMD, which directly cues the unique gene association.\nMain medical accuracy issues: None; pathophysiologic association and clinical context are up to date and standard.\nMinimal fix: No essential change needed; optionally add that the mutation is somatic in megakaryoblasts to increase precision.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-012", "question": "A 2-year-old boy presents with eczema, thrombocytopenia, and recurrent pyogenic infections. He has small platelets on peripheral smear. Genetic testing reveals a mutation in the WAS gene. Which of the following malignancies is this patient at the highest risk of developing?", "options": ["Non-Hodgkin Lymphoma", "Acute Myeloid Leukemia", "Neuroblastoma", "Hepatoblastoma", "Osteosarcoma"], "answer": "A", "answer_index": 0, "explanation": "Wiskott-Aldrich Syndrome (WAS) is an X-linked disorder characterized by the triad of eczema, immunodeficiency, and thrombocytopenia with small platelets. Due to defective T-cell function and immune surveillance, these patients have a significantly elevated risk of lymphoreticular malignancies, particularly Non-Hodgkin Lymphoma (often EBV-positive).", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 2-year-old boy; eczema, thrombocytopenia, recurrent pyogenic infections; small platelets; WAS gene mutation → classic Wiskott-Aldrich syndrome. Wiskott-Aldrich is known to carry a markedly increased risk of lymphoreticular malignancies (especially non-Hodgkin lymphoma, often EBV-associated) due to combined T- and B-cell immunodeficiency and impaired immune surveillance. Among the listed options, non-Hodgkin lymphoma is the only lymphoreticular cancer and the clearly highest-risk malignancy for this syndrome.\\nOther options: Acute myeloid leukemia (B) is not classically associated with WAS; leukemia risk is much less emphasized than lymphoma. Neuroblastoma (C), hepatoblastoma (D), and osteosarcoma (E) have no specific increased association with WAS and are background pediatric cancer risks.\\nMain logical issues: None; the question is specific, and choices are clearly distinguishable. No internal contradictions or need for unstated assumptions.\\nMain medical accuracy issues: None; pathophysiology and malignancy association are correct and up to date for board level.\\nMinimal fix: None required; optionally, adding “lymphoid malignancy” in the explanation further reinforces the teaching point but item is already clear and valid.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 2-year-old boy; eczema, thrombocytopenia, recurrent pyogenic infections; small platelets; WAS gene mutation → classic Wiskott-Aldrich syndrome. Wiskott-Aldrich is known to carry a markedly increased risk of lymphoreticular malignancies (especially non-Hodgkin lymphoma, often EBV-associated) due to combined T- and B-cell immunodeficiency and impaired immune surveillance. Among the listed options, non-Hodgkin lymphoma is the only lymphoreticular cancer and the clearly highest-risk malignancy for this syndrome.\nOther options: Acute myeloid leukemia (B) is not classically associated with WAS; leukemia risk is much less emphasized than lymphoma. Neuroblastoma (C), hepatoblastoma (D), and osteosarcoma (E) have no specific increased association with WAS and are background pediatric cancer risks.\nMain logical issues: None; the question is specific, and choices are clearly distinguishable. No internal contradictions or need for unstated assumptions.\nMain medical accuracy issues: None; pathophysiology and malignancy association are correct and up to date for board level.\nMinimal fix: None required; optionally, adding “lymphoid malignancy” in the explanation further reinforces the teaching point but item is already clear and valid.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-013", "question": "A patient with a dual-chamber pacemaker programmed to DDD mode undergoes surgery. A magnet is placed over the device to prevent electromagnetic interference (EMI) from electrocautery. The pacemaker battery is known to be at the 'Elective Replacement Indicator' (ERI) voltage level. What is the most likely response of the pacemaker to the magnet application?", "options": ["Reversion to asynchronous DOO mode at the magnet rate", "Reversion to asynchronous VOO mode at the magnet rate", "No change in mode or rate (magnet response disabled)", "Inhibition of all pacing", "Reversion to VVI mode"], "answer": "C", "answer_index": 2, "explanation": "Normally, magnet application converts a pacemaker to an asynchronous mode (DOO/VOO) at a specific magnet rate. However, many modern pacemakers are programmed to disable the magnet response when the battery voltage drops to the Elective Replacement Indicator (ERI) or End of Life (EOL) level to conserve power or signal the battery status. Therefore, the magnet may fail to protect against EMI in this specific scenario.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (underspecified). Verdict on keyed answer: Not uniquely determinable. The stem: dual‑chamber pacemaker in DDD mode, magnet applied during surgery, battery at ERI. It asks for the *most likely* magnet response. The explanation asserts that “many modern pacemakers” disable magnet response at ERI/EOL, leading to no change, which matches option C. However, magnet behavior at ERI is highly device‑ and manufacturer‑specific: some continue to revert to asynchronous DOO/VOO at a changed magnet rate (battery test rate), others may alter mode (e.g., VVI) or still show a magnet response. The stem gives no device make/model or programming details, so the exact response cannot be inferred from standard physiology or guidelines alone. Thus the keyed answer depends on an unstated assumption about a specific manufacturer behavior and is not uniquely defensible as a general rule. Medically, the generic description of magnet behavior (asynchronous mode at a magnet rate, ERI potentially altering response) is broadly accurate but oversimplified. Minimal fix: specify a particular manufacturer/model and its known ERI magnet response pattern, or state that the device’s magnet response was disabled at ERI in device interrogation data, to support option C unambiguously.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (underspecified). Verdict on keyed answer: Not uniquely determinable. The stem: dual‑chamber pacemaker in DDD mode, magnet applied during surgery, battery at ERI. It asks for the *most likely* magnet response. The explanation asserts that “many modern pacemakers” disable magnet response at ERI/EOL, leading to no change, which matches option C. However, magnet behavior at ERI is highly device‑ and manufacturer‑specific: some continue to revert to asynchronous DOO/VOO at a changed magnet rate (battery test rate), others may alter mode (e.g., VVI) or still show a magnet response. The stem gives no device make/model or programming details, so the exact response cannot be inferred from standard physiology or guidelines alone. Thus the keyed answer depends on an unstated assumption about a specific manufacturer behavior and is not uniquely defensible as a general rule. Medically, the generic description of magnet behavior (asynchronous mode at a magnet rate, ERI potentially altering response) is broadly accurate but oversimplified. Minimal fix: specify a particular manufacturer/model and its known ERI magnet response pattern, or state that the device’s magnet response was disabled at ERI in device interrogation data, to support option C unambiguously.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-014", "question": "A patient undergoing general anesthesia with desflurane develops a rapid increase in end-tidal CO2 and tachycardia. Malignant Hyperthermia (MH) is suspected. The anesthesia machine is flushed, and dantrolene is administered. Which of the following calcium channel blockers is absolutely contraindicated in the acute management of this patient?", "options": ["Amlodipine", "Diltiazem", "Verapamil", "Nicardipine", "Nimodipine"], "answer": "C", "answer_index": 2, "explanation": "Verapamil (and diltiazem) is contraindicated in the setting of Malignant Hyperthermia, especially when dantrolene is administered. The combination of dantrolene and calcium channel blockers can lead to profound hyperkalemia and cardiovascular collapse/myocardial depression.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed)\\nVerdict on keyed answer: Miskeyed\\nKey stem clues: Malignant hyperthermia during desflurane anesthesia; dantrolene already administered; question explicitly asks: “Which of the following calcium channel blockers is absolutely contraindicated in the acute management of this patient?” The explanation notes that the combination of dantrolene and *calcium channel blockers* can cause serious complications.\\nThe major evidence-based contraindication is with non–dihydropyridine calcium channel blockers (verapamil and diltiazem) when given with dantrolene, due to risk of hyperkalemia and cardiovascular collapse. However, the rationale itself explicitly states “Verapamil (and diltiazem) is contraindicated,” yet the question asks for a single best option and offers both verapamil and diltiazem among the choices. Both are equally contraindicated and thus defensible, so the item is logically flawed. The keyed answer C (verapamil) is not uniquely best relative to B (diltiazem).\\nMain medical accuracy issue: The pathophysiology and guidance are otherwise correct; the problem is exclusivity, not content.\\nMinimal fix: Either change the stem to “Which of the following *pairs* includes a drug absolutely contraindicated…?” or remove diltiazem from the options so that verapamil is uniquely correct.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed)\nVerdict on keyed answer: Miskeyed\nKey stem clues: Malignant hyperthermia during desflurane anesthesia; dantrolene already administered; question explicitly asks: “Which of the following calcium channel blockers is absolutely contraindicated in the acute management of this patient?” The explanation notes that the combination of dantrolene and *calcium channel blockers* can cause serious complications.\nThe major evidence-based contraindication is with non–dihydropyridine calcium channel blockers (verapamil and diltiazem) when given with dantrolene, due to risk of hyperkalemia and cardiovascular collapse. However, the rationale itself explicitly states “Verapamil (and diltiazem) is contraindicated,” yet the question asks for a single best option and offers both verapamil and diltiazem among the choices. Both are equally contraindicated and thus defensible, so the item is logically flawed. The keyed answer C (verapamil) is not uniquely best relative to B (diltiazem).\nMain medical accuracy issue: The pathophysiology and guidance are otherwise correct; the problem is exclusivity, not content.\nMinimal fix: Either change the stem to “Which of the following *pairs* includes a drug absolutely contraindicated…?” or remove diltiazem from the options so that verapamil is uniquely correct.\n", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-015", "question": "A 65-year-old male presents with new-onset intention tremor and gait ataxia. MRI reveals T2 hyperintensities in the middle cerebellar peduncles (MCP sign). He has a grandson with intellectual disability. What is the molecular mechanism of the grandfather's condition?", "options": ["CGG repeat expansion > 200 causing gene methylation and silencing", "CGG repeat expansion between 55 and 200 causing mRNA toxicity", "CAG repeat expansion causing polyglutamine aggregation", "CTG repeat expansion causing RNA foci formation", "Deletion of the FMR1 gene"], "answer": "B", "answer_index": 1, "explanation": "The patient has Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). This occurs in 'premutation' carriers (55-200 CGG repeats) of the FMR1 gene. Unlike Fragile X syndrome (>200 repeats, gene silencing/methylation), FXTAS is caused by a 'toxic gain-of-function' where elevated levels of FMR1 mRNA containing the repeats sequester RNA-binding proteins, leading to neurotoxicity.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Elderly male (65) with new-onset intention tremor and gait ataxia, MRI showing T2 hyperintensities in the middle cerebellar peduncles (MCP sign), and a grandson with intellectual disability. This classic constellation points to Fragile X–associated Tremor/Ataxia Syndrome (FXTAS) in a premutation FMR1 carrier. The molecular mechanism is toxic gain-of-function from elevated premutation-range CGG-repeat FMR1 mRNA causing mRNA toxicity.\\nOption B precisely describes “CGG repeat expansion between 55 and 200 causing mRNA toxicity,” matching FXTAS pathophysiology. Option A (>200 CGG with methylation/silencing) and E (deletion) both describe full mutation/complete loss of FMR1 seen in Fragile X syndrome, not FXTAS. C (CAG polyglutamine) refers to Huntington and other spinocerebellar ataxias. D (CTG repeat) refers to myotonic dystrophy; not associated with MCP sign or this pedigree pattern.\\nNo major logical flaws or ambiguities; the stem provides sufficient discriminating details to support a single best answer that matches the key.\\nMinimal fix: Clarify that the grandson’s intellectual disability is due to Fragile X syndrome to make the pedigree context explicit, though it is already strongly implied.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Elderly male (65) with new-onset intention tremor and gait ataxia, MRI showing T2 hyperintensities in the middle cerebellar peduncles (MCP sign), and a grandson with intellectual disability. This classic constellation points to Fragile X–associated Tremor/Ataxia Syndrome (FXTAS) in a premutation FMR1 carrier. The molecular mechanism is toxic gain-of-function from elevated premutation-range CGG-repeat FMR1 mRNA causing mRNA toxicity.\nOption B precisely describes “CGG repeat expansion between 55 and 200 causing mRNA toxicity,” matching FXTAS pathophysiology. Option A (>200 CGG with methylation/silencing) and E (deletion) both describe full mutation/complete loss of FMR1 seen in Fragile X syndrome, not FXTAS. C (CAG polyglutamine) refers to Huntington and other spinocerebellar ataxias. D (CTG repeat) refers to myotonic dystrophy; not associated with MCP sign or this pedigree pattern.\nNo major logical flaws or ambiguities; the stem provides sufficient discriminating details to support a single best answer that matches the key.\nMinimal fix: Clarify that the grandson’s intellectual disability is due to Fragile X syndrome to make the pedigree context explicit, though it is already strongly implied.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-016", "question": "A patient with bipolar disorder is stable on valproate. He develops a severe infection and is prescribed meropenem. Within 48 hours, his manic symptoms recur. What is the mechanism of this drug interaction?", "options": ["Meropenem inhibits CYP2C9, increasing valproate toxicity", "Meropenem displaces valproate from albumin", "Meropenem increases the glucuronidation and renal clearance of valproate", "Meropenem acts as a direct dopamine agonist", "Meropenem induces CYP3A4, lowering valproate levels"], "answer": "C", "answer_index": 2, "explanation": "Carbapenems (like meropenem) dramatically reduce serum valproate levels, often by 50-80% within 24 hours. The mechanism involves the inhibition of acylpeptide hydrolase (which normally deconjugates valproate-glucuronide back to valproate) and increased renal clearance of the glucuronide metabolite. This interaction is rapid and can precipitate decompensation.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Patient is stable on valproate, then starts meropenem; within 48 hours manic symptoms recur. This points to a rapid, marked fall in valproate levels due to a known carbapenem–valproate interaction causing loss of mood stabilization. The explanation given correctly notes meropenem’s inhibition of acylpeptide hydrolase, which impairs deconjugation of valproate-glucuronide and increases renal clearance of the conjugate, thereby lowering active valproate.\\nOption analysis: A (CYP2C9 inhibition) and E (CYP3A4 induction) are incorrect; carbapenem–valproate interaction is not via major CYP pathways. B (albumin displacement) would acutely increase free valproate, potentially toxicity, opposite the clinical scenario. D (direct dopamine agonist) is pharmacologically false for meropenem. C, though slightly simplified, best reflects the increased glucuronidation/clearance pathway described in the rationale and matches current pharmacology knowledge.\\nMain issues: Minor mechanistic oversimplification—the key step is inhibition of deconjugation rather than increased formation of glucuronide—but not misleading clinically.\\nMinimal fix: Reword C to “Meropenem inhibits deconjugation of valproate-glucuronide, leading to increased renal clearance of the glucuronide and reduced valproate levels.”\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Patient is stable on valproate, then starts meropenem; within 48 hours manic symptoms recur. This points to a rapid, marked fall in valproate levels due to a known carbapenem–valproate interaction causing loss of mood stabilization. The explanation given correctly notes meropenem’s inhibition of acylpeptide hydrolase, which impairs deconjugation of valproate-glucuronide and increases renal clearance of the conjugate, thereby lowering active valproate.\nOption analysis: A (CYP2C9 inhibition) and E (CYP3A4 induction) are incorrect; carbapenem–valproate interaction is not via major CYP pathways. B (albumin displacement) would acutely increase free valproate, potentially toxicity, opposite the clinical scenario. D (direct dopamine agonist) is pharmacologically false for meropenem. C, though slightly simplified, best reflects the increased glucuronidation/clearance pathway described in the rationale and matches current pharmacology knowledge.\nMain issues: Minor mechanistic oversimplification—the key step is inhibition of deconjugation rather than increased formation of glucuronide—but not misleading clinically.\nMinimal fix: Reword C to “Meropenem inhibits deconjugation of valproate-glucuronide, leading to increased renal clearance of the glucuronide and reduced valproate levels.”", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-017", "question": "In the forensic evaluation of a defendant's competency to stand trial (CST), which legal standard is the primary precedent in the United States?", "options": ["Durham v. United States", "Dusky v. United States", "M'Naghten Rule", "Tarasoff v. Regents of the University of California", "Ford v. Wainwright"], "answer": "B", "answer_index": 1, "explanation": "Dusky v. United States (1960) established the standard for Competency to Stand Trial. The defendant must have a 'sufficient present ability to consult with his lawyer with a reasonable degree of rational understanding' and a 'rational as well as factual understanding of the proceedings against him.' M'Naghten and Durham relate to the insanity defense (NGRI), not competency.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: The question explicitly asks about the “forensic evaluation of a defendant’s competency to stand trial (CST)” and the “primary precedent in the United States.” The options are landmark U.S. cases/rules. Dusky v. United States is the well-established precedent defining CST: sufficient present ability to consult with counsel with a reasonable degree of rational understanding and both rational and factual understanding of proceedings.\\nEvaluation of alternatives: M’Naghten Rule and Durham v. United States address insanity (criminal responsibility), not competency. Tarasoff v. Regents concerns duty to warn/protect, unrelated to CST. Ford v. Wainwright concerns competency to be executed, not competency to stand trial. Thus only Dusky directly and primarily addresses CST.\\nMain logical issues: None; the stem is clear, and each alternative is plausibly related to forensic psychiatry but distinguishable, allowing a single best answer.\\nMain medical accuracy issues: None; the legal standard is correctly named and accurately summarized in the explanation.\\nMinimal fix: None required; optionally, adding the year (1960) in the stem or explanation is already present and appropriate but not necessary for clarity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: The question explicitly asks about the “forensic evaluation of a defendant’s competency to stand trial (CST)” and the “primary precedent in the United States.” The options are landmark U.S. cases/rules. Dusky v. United States is the well-established precedent defining CST: sufficient present ability to consult with counsel with a reasonable degree of rational understanding and both rational and factual understanding of proceedings.\nEvaluation of alternatives: M’Naghten Rule and Durham v. United States address insanity (criminal responsibility), not competency. Tarasoff v. Regents concerns duty to warn/protect, unrelated to CST. Ford v. Wainwright concerns competency to be executed, not competency to stand trial. Thus only Dusky directly and primarily addresses CST.\nMain logical issues: None; the stem is clear, and each alternative is plausibly related to forensic psychiatry but distinguishable, allowing a single best answer.\nMain medical accuracy issues: None; the legal standard is correctly named and accurately summarized in the explanation.\nMinimal fix: None required; optionally, adding the year (1960) in the stem or explanation is already present and appropriate but not necessary for clarity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-018", "question": "A 40-year-old female presents with a 3 cm mass in the tail of the pancreas. CT imaging shows a well-circumscribed lesion with peripheral calcification. EUS-FNA is non-diagnostic but shows glycogen-rich cuboidal cells. What is the most likely diagnosis?", "options": ["Serous cystadenoma", "Mucinous cystic neoplasm", "Solid pseudopapillary neoplasm", "Pancreatic neuroendocrine tumor", "Acinar cell carcinoma"], "answer": "A", "answer_index": 0, "explanation": "Serous cystadenomas are benign lesions often found in the pancreatic tail. The classic description includes a 'honeycomb' appearance and a central scar with calcification (though peripheral calcification can occur). The key histologic feature is glycogen-rich cuboidal cells (clear cells) that stain positive for PAS. They have virtually no malignant potential.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 40-year-old woman; 3-cm well-circumscribed tail lesion; peripheral calcification; EUS-FNA with glycogen-rich cuboidal (clear) cells. These findings strongly support a pancreatic serous cystadenoma. Serous cystadenomas are typically microcystic, well-circumscribed, more common in women, often in the body/tail, and composed of glycogen-rich clear cuboidal cells on histology. Central stellate scar with calcification is classic, but peripheral calcification is compatible.\\nOther options: Mucinous cystic neoplasm usually shows mucin-producing epithelium and ovarian-type stroma, not glycogen-rich cuboidal cells. Solid pseudopapillary neoplasm affects young women and is solid-cystic with characteristic pseudopapillary architecture, not clear glycogen-rich cuboidal cells. Pancreatic neuroendocrine tumors have neuroendocrine cytology and markers, not glycogen-rich clear cells. Acinar cell carcinoma shows acinar differentiation with zymogen granules rather than clear, glycogen-rich cuboidal cells.\\nMain medical accuracy issues: Minor—central rather than peripheral calcification is more classic, but explanation acknowledges this. Overall pathology correlation is accurate.\\nMinimal fix: Clarify imaging description to “well-circumscribed pancreatic tail lesion with central stellate scar and calcification” to better match the classic serous cystadenoma description and avoid confusion.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 40-year-old woman; 3-cm well-circumscribed tail lesion; peripheral calcification; EUS-FNA with glycogen-rich cuboidal (clear) cells. These findings strongly support a pancreatic serous cystadenoma. Serous cystadenomas are typically microcystic, well-circumscribed, more common in women, often in the body/tail, and composed of glycogen-rich clear cuboidal cells on histology. Central stellate scar with calcification is classic, but peripheral calcification is compatible.\nOther options: Mucinous cystic neoplasm usually shows mucin-producing epithelium and ovarian-type stroma, not glycogen-rich cuboidal cells. Solid pseudopapillary neoplasm affects young women and is solid-cystic with characteristic pseudopapillary architecture, not clear glycogen-rich cuboidal cells. Pancreatic neuroendocrine tumors have neuroendocrine cytology and markers, not glycogen-rich clear cells. Acinar cell carcinoma shows acinar differentiation with zymogen granules rather than clear, glycogen-rich cuboidal cells.\nMain medical accuracy issues: Minor—central rather than peripheral calcification is more classic, but explanation acknowledges this. Overall pathology correlation is accurate.\nMinimal fix: Clarify imaging description to “well-circumscribed pancreatic tail lesion with central stellate scar and calcification” to better match the classic serous cystadenoma description and avoid confusion.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-019", "question": "During a laparoscopic inguinal hernia repair (TEP), the surgeon encounters significant bleeding from an aberrant vessel crossing the superior pubic ramus, connecting the external iliac and obturator systems. This vessel is known as:", "options": ["Circle of Willis", "Corona Mortis", "Arc of Riolan", "Marginal Artery of Drummond", "Batson's Plexus"], "answer": "B", "answer_index": 1, "explanation": "The 'Corona Mortis' (Crown of Death) is a vascular connection between the obturator and external iliac systems (usually an aberrant obturator artery arising from the inferior epigastric). It crosses the superior pubic ramus in the Space of Retzius and is at high risk of injury during laparoscopic hernia repair or pelvic trauma, leading to difficult-to-control hemorrhage.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Laparoscopic inguinal hernia repair (TEP), bleeding from an aberrant vessel crossing the superior pubic ramus, connection between external iliac and obturator systems. This precisely describes the corona mortis, an anastomotic vessel (arterial and/or venous) between the external iliac/inferior epigastric and obturator systems, running over the superior pubic ramus in the retropubic (Retzius) space and notorious for severe bleeding when injured.\\nAlternative choices: Circle of Willis (intracranial arterial circle, unrelated to pelvis); Arc of Riolan and Marginal artery of Drummond (mesenteric colonic arterial arcades), wrong location/system; Batson’s plexus (valveless vertebral venous plexus), also wrong location and vessel type.\\nMain logical issues: None; stem is specific and highly discriminating; only one option fits.\\nMain medical accuracy issues: Minor nuance—corona mortis may be arterial and/or venous; the explanation emphasizes aberrant obturator artery from inferior epigastric but is still acceptable and commonly taught.\\nMinimal fix: Add “which may be arterial and/or venous” to the explanation to reflect anatomic variability more precisely.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Laparoscopic inguinal hernia repair (TEP), bleeding from an aberrant vessel crossing the superior pubic ramus, connection between external iliac and obturator systems. This precisely describes the corona mortis, an anastomotic vessel (arterial and/or venous) between the external iliac/inferior epigastric and obturator systems, running over the superior pubic ramus in the retropubic (Retzius) space and notorious for severe bleeding when injured.\nAlternative choices: Circle of Willis (intracranial arterial circle, unrelated to pelvis); Arc of Riolan and Marginal artery of Drummond (mesenteric colonic arterial arcades), wrong location/system; Batson’s plexus (valveless vertebral venous plexus), also wrong location and vessel type.\nMain logical issues: None; stem is specific and highly discriminating; only one option fits.\nMain medical accuracy issues: Minor nuance—corona mortis may be arterial and/or venous; the explanation emphasizes aberrant obturator artery from inferior epigastric but is still acceptable and commonly taught.\nMinimal fix: Add “which may be arterial and/or venous” to the explanation to reflect anatomic variability more precisely.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-020", "question": "A patient with a history of rhegmatogenous retinal detachment repair with silicone oil tamponade presents with inferior visual field loss in the same eye. Intraocular pressure is 35 mmHg. Gonioscopy reveals silicone oil emulsification in the superior angle. What is the mechanism of this glaucoma?", "options": ["Pupillary block", "Trabecular meshwork obstruction by emulsified oil droplets", "Ciliary body inflammation", "Schlemm's canal collapse", "Angle closure due to anterior displacement of the lens-iris diaphragm"], "answer": "B", "answer_index": 1, "explanation": "Silicone oil is lighter than water (aqueous humor) and floats. Over time, it can emulsify into small droplets. These droplets float into the superior angle (unlike pigment or pseudoexfoliation material which settles inferiorly) and physically obstruct the trabecular meshwork, causing secondary open-angle glaucoma. This is sometimes called 'inverse hypopyon'.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Ophthalmology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Prior rhegmatogenous retinal detachment repair with silicone oil tamponade; current IOP 35 mmHg; gonioscopy specifically shows silicone oil emulsification in the superior angle; inferior visual field loss consistent with glaucomatous damage. These features clearly indicate a secondary open-angle glaucoma from silicone oil droplets blocking the trabecular meshwork.\\n\\nThe explanation that silicone oil is lighter than aqueous, floats superiorly, and when emulsified can obstruct the superior trabecular meshwork is pathophysiologically correct. This directly supports option B.\\n\\nOther options are less defensible: A (pupillary block) is not suggested by angle findings or clinical description; C (ciliary body inflammation) would imply uveitic glaucoma, not supported by the stem; D (Schlemm’s canal collapse) is not the typical mechanism here; E (angle closure from anterior displacement of lens-iris diaphragm) would show angle narrowing/closure, not just emulsified oil in the angle.\\n\\nNo major logical or medical inaccuracies are evident. The stem is sufficiently specified to uniquely indicate trabecular obstruction by emulsified silicone oil.\\n\\nMinimal fix: Optionally add “open angle on gonioscopy” to the stem to further emphasize the open-angle mechanism, though it is already implied by the described finding.\",\n  \"medical_accuracy_score\": \"5\",\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Prior rhegmatogenous retinal detachment repair with silicone oil tamponade; current IOP 35 mmHg; gonioscopy specifically shows silicone oil emulsification in the superior angle; inferior visual field loss consistent with glaucomatous damage. These features clearly indicate a secondary open-angle glaucoma from silicone oil droplets blocking the trabecular meshwork.\n\nThe explanation that silicone oil is lighter than aqueous, floats superiorly, and when emulsified can obstruct the superior trabecular meshwork is pathophysiologically correct. This directly supports option B.\n\nOther options are less defensible: A (pupillary block) is not suggested by angle findings or clinical description; C (ciliary body inflammation) would imply uveitic glaucoma, not supported by the stem; D (Schlemm’s canal collapse) is not the typical mechanism here; E (angle closure from anterior displacement of lens-iris diaphragm) would show angle narrowing/closure, not just emulsified oil in the angle.\n\nNo major logical or medical inaccuracies are evident. The stem is sufficiently specified to uniquely indicate trabecular obstruction by emulsified silicone oil.\n\nMinimal fix: Optionally add “open angle on gonioscopy” to the stem to further emphasize the open-angle mechanism, though it is already implied by the described finding.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]